Overview

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade non-Hodgkin lymphoma (NHL).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York Medical College
Treatments:
Clofarabine
Mitoxantrone